Gang (Gavin) Liu

Gang (Gavin) Liu has extensive experience in the field of pharmaceuticals and biotechnology. Gang (Gavin) currently serves as Head of CMC at AffyImmune Therapeutics. Prior to this, they were Associate Director, Cell Therapy & Process Development and Principal Scientist, Cell Therapy & Process Development at Simcere Pharmaceutical Group from 2019-2021. During this time, they were the lead of process development on CARNK allogenic product pipeline and lead of tech transfer to internal manufacture team and external CMO facility. Gang (Gavin) was also the project lead of RD and early PD on HSC-CARNK/macrophage pipeline targeting solid tumors. From 2018-2019, they were the Sr. Scientist, Process Development (CAR T/ Stem Cell Gene Therapy) at Mustang Bio, where they worked on the full process development of MB102 (CD123 CART) and MB107 (SCID stem cell gene therapy) from cell isolation, expansion, transduction, harvest, formulation and cryopreservation. Gang (Gavin) was also the PD team leader of analytical assays (FACS, ELISA and QPCR) development and data analysis, and team leader on coordinating with academic PD team (City of Hope) to implement tech transfer. From 2008-2018, they were a Research Scientist and Senior Fellow at the University of Washington, where they identified the expression and function of constitutively active androgen receptor (AR) splice variant ARv567es in castration-resistant prostate cancer, and pre-clinical tested a broad range of anti-prostate cancer drugs with engineered cancer cell lines, xenografts and transgenic mouse models. Gang (Gavin) also developed therapeutic antibody targeting soluble MIC to reactivate innate NK cell immune through MIC-NKD2D interaction for prostate cancer treatment, and preclinically investigated the anti-MIC antibody on engineered MIC-shedding/non-shedding prostate cancer models.

Gang (Gavin) Liu has completed a Postdoc Fellowship at the University of California, San Francisco, where they studied Molecular Urology/ Stem Cell. Prior to this, they obtained a Ph.D in Surgery (Molecular Urology) from Peking University.